Loading
A phase 3 trial of IGI, 10% in multiple myeloma, run by Takeda, now recruiting.
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma is a phase 3 interventional study registered as NCT06980480 by Takeda, with 183 participants planned, started 2026-01-14 and due to reach its primary completion in 2028-09-11. Interventions recorded: IGI, 10%.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/